Today: 10 April 2026

Real-time market monitoring

Browse Category

ASX:CSL 28 November 2025 - 22 December 2025

CSL Limited (ASX:CSL) Stock Update: Share Price, Buyback Progress, Analyst Forecasts and Key Catalysts as of 22 December 2025

CSL Limited shares closed at A$176.31 on 22 December 2025, up 0.7% for the day but down 37.6% for the year. The company reported buying back 65,217 shares on 17 December, bringing its total buyback to about A$588 million as it targets up to A$750 million by June 2026. Investors remain focused on ongoing restructuring and uncertainty in the Seqirus vaccine unit.

22 December 2025

ASX:CSL·Stock Market

Australia Stock Market Today: ASX 200 Rises as Miners, Energy and Record Gold Lift Shares (22 December 2025)

Australia’s S&P/ASX 200 rose 0.9% to around 8,701 by early afternoon Monday, led by gains in miners and energy stocks as commodity prices climbed. Nick Scali jumped 10% after upgrading its first-half outlook. Uranium stocks rallied, while WiseTech Global fell about 3%. Investors awaited RBA minutes and monitored new federal gas export rules.

22 December 2025

ASX:BHP·ASX:CBA·ASX:CSL·ASX:NAB·ASX:RIO·ASX:WTC·Energy·Gold·Stock Market

CSL Limited Stock (ASX: CSL) Outlook on 21 December 2025: Seqirus Spin-Off Delay, Buyback Momentum, and Analyst Price Targets

CSL shares closed at A$175.08 on Friday, down nearly 37% over the past year amid sharp volatility and a revised FY2026 outlook. The company cut revenue and profit growth targets at its October AGM and delayed the planned Seqirus demerger, citing weaker US flu vaccination rates and pricing pressure in China. CSL continues a steady on-market buyback while investing in US manufacturing.

21 December 2025

ASX Updates·ASX:CSL

CSL Limited Stock (ASX:CSL): Latest News, Buyback Update, Analyst Price Targets and 2026 Outlook (20 Dec 2025)

CSL Limited shares traded near A$175 in mid-December, close to 52-week lows after a year of vaccine-market volatility and a delayed Seqirus spin-off. The company has spent about A$588 million on its A$750 million share buyback, with roughly A$160 million capacity remaining. CSL also announced a US$1.5 billion investment to expand U.S. plasma-therapy manufacturing.

20 December 2025

ASX:CSL

CSL Limited Stock (ASX: CSL): Buyback Update, Analyst Forecasts, and the Key Catalysts Shaping the CSL Share Price on 18 December 2025

CSL Limited updated its on-market buyback on 18 December 2025, reporting 65,217 shares repurchased on 17 December for A$11.37 million. The stock closed at A$174.57, up 0.68%, with a market cap near A$84.7 billion. Shares remain far below the 52-week high of A$288.33 after weak flu vaccine demand and uncertainty in China. The buyback program is capped at A$750 million through June 2026.

18 December 2025

ASX:CSL·Stock Market

CSL Limited Stock (ASX:CSL) Today: Buyback Update, Macquarie Downgrade, and What Analysts Forecast for 2026 (Dec 17, 2025)

CSL Limited shares closed at A$172.77 on December 17, down 2.47% after a new buyback update and continued broker downgrades. The company disclosed it repurchased 74,399 shares on December 16, bringing the total to 2,955,365 shares for about A$577.05 million. Macquarie downgraded CSL to Neutral and cut its price target.

17 December 2025

ASX:CSL

CSL Limited Stock (ASX:CSL): Buyback Update, Analyst Price Targets and the 2026 Outlook (16 Dec 2025)

CSL shares closed at A$177.26 on December 16, down 1.15%, as investors reacted to a new buyback update and ongoing uncertainty over earnings growth. The company disclosed it repurchased 60,491 shares for A$10.9 million on December 15, part of an up to A$750 million buyback running through June 2026. Market focus remains on CSL Seqirus guidance and margin recovery at CSL Behring.

16 December 2025

ASX Updates·ASX:CSL·Stock Market

CSL Limited Stock (ASX: CSL) Sinks on Macquarie Downgrade: Today’s News, Analyst Forecasts, and the 2026 Catalysts Investors Are Watching

CSL shares traded near A$180 on December 15, 2025, after Macquarie downgraded the stock to Neutral and cut its target price by 32% to A$188. CSL reported buying back 46,950 shares on December 12, bringing its total buy-back to over 2.8 million shares. The stock is down about 35% for the year amid broker concerns over China albumin market pressures and increased competition.

15 December 2025

ASX:CSL·Stock Market

CSL Limited Stock (ASX:CSL) Update: Hemgenix 5-Year Data, Vaccine Audit Fallout, Buyback Support — Week Ahead Outlook (Updated 14 Dec 2025)

CSL shares closed Friday at A$183.93, up 2.86% on the day but down 0.85% for the week. The company reported five-year data for its hemophilia B gene therapy HEMGENIX, showing 94% of patients remained free from continuous treatment. Investors also weighed scrutiny of CSL Seqirus vaccine deals and the ongoing A$750 million buyback.

14 December 2025

ASX:CSL·Biotechnology·Pharmaceutical Industry

CSL Limited Stock (ASX:CSL) After the Bell on Dec. 12, 2025: Buyback Update, HEMGENIX Five‑Year Data, Analyst Forecasts, and What to Watch Before the Next Open

CSL (ASX:CSL) closed at A$183.93 on Friday, up 2.86% after announcing it bought back 52,154 shares for A$9.35 million the previous day. Trading volume reached about 969,000 shares. The S&P/ASX 200 rose 1.23%, with healthcare stocks outperforming. CSL has spent about A$544.3 million of its planned A$750 million buyback since September.

13 December 2025

ASX:CSL·Share Buybacks·Stock Market

CSL Limited (ASX: CSL) Stock News Today: Buyback Update, Seqirus Uncertainty, and Analyst Forecasts for 2026

CSL Limited disclosed on December 12 it bought back 52,154 shares for A$9.35 million the previous day, bringing total buybacks to 2,721,371 shares and A$534.98 million under its A$750 million program. Shares traded around A$182.42 intraday. The buyback, managed by UBS, is set to run until June 2026. Investors remain focused on vaccine demand volatility and delays in the Seqirus spin-off.

12 December 2025

ASX:CSL·Stock Market

CSL Limited (ASX:CSL) Share Price Near $180: Latest News, Analyst Forecasts and 2026 Outlook as at 10 December 2025

CSL shares traded near A$181 on 10 December 2025, down about 30% for the year and near the bottom of their 52-week range. The company resumed its share buy-back, acquiring over 2.6 million shares so far. Analysts maintain a buy rating with a price target of A$256. A federal audit criticized CSL’s A$1 billion Seqirus vaccine deal earlier in the week.

10 December 2025

ASX:CSL·Stock Market

Best ASX Stocks to Buy Now (10 December 2025): 10 Australian Shares to Watch After the RBA Pause

The S&P/ASX 200 closed at 8,585.90 on December 9, 2025, near record highs, as the Reserve Bank of Australia left rates at 3.60% and warned of possible hikes in 2026. Resources stocks gained 23% over the year, while IT slumped. Major blue-chip names fell sharply from 12-month highs as investors shifted to mid-caps and cyclicals. Data center demand is surging, with capacity projected to lag AI-driven needs by 2028.

10 December 2025

ASX:CBA·ASX:CSL·ASX:WTC·Stock Market

CSL Limited (ASX:CSL) Stock Outlook 2026: Is the Biotech Giant Finally a Buy After a 35% Sell-Off?

CSL shares traded at A$184–186 on 9 December 2025, down about 35% from their January peak. The stock plunged after profit downgrades, a delayed Seqirus spin-off, job cuts, and weaker US vaccination rates. Net profit after tax for FY25 rose 17% to US$3.0 billion, but guidance for FY26 was cut at the October AGM. Market value remains near A$90 billion.

9 December 2025

ASX:CSL

CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL shares closed at A$182.43 on 5 December 2025, near multi-year lows after restructuring, a guidance cut, and a delayed vaccines spin-off. The company has repurchased over 2.5 million shares under a new buyback and opened a A$1 billion vaccine and antivenom plant in Melbourne. Market cap stands near A$89 billion, with shares down about 35% over 12 months.

5 December 2025

ASX Updates·ASX:CSL·Financial Forecasts·Stock Market

CSL Limited (ASX:CSL) Share Price on 4 December 2025: Restructuring Fallout, New Vaccine Plant and 2026 Stock Forecast

CSL Limited shares traded at A$183 on 4 December 2025, down about 35% year-to-date and near the bottom of their 52-week range. The company opened a A$1 billion vaccine and antivenom plant in Melbourne this week and launched a A$750 million buy-back. Market value stands near A$88–89 billion, roughly one-third lower than a year ago.

4 December 2025

ASX Updates·ASX:CSL

CSL Limited (ASX:CSL) Stock Outlook on 2 December 2025: Share Price Slump, Seqirus Spin-Off, New Vaccine Plant and a A$750m Buyback

CSL shares traded at A$182.42 midday Monday, down 0.7%, extending a 35% slide for 2025 despite strong earnings growth. The stock remains far below its 52-week high of A$290 after a sharp drop in August, when CSL announced a major restructuring and plans to spin off its vaccines arm. A broader ASX sell-off and sector weakness added pressure.

2 December 2025

ASX:CSL·Stock Market

CSL Limited (ASX:CSL) Share Price, Latest News and 2026 Outlook as of 1 December 2025

CSL closed at about A$186.30 on 28 November 2025, down roughly 34–35% for the year. Shares plunged 16–17% in late October after CSL cut its FY26 outlook and delayed the Seqirus vaccine spin-off, citing a sharp drop in US flu vaccination rates. More than 40% of shareholders rejected the executive pay report at the AGM, triggering a second strike. Market cap stands near A$90 billion.

1 December 2025

ASX News·ASX:CSL·Stock Market

CSL Limited (ASX:CSL) Shares: Cost Cuts, Buyback and US Expansion – What to Watch Before the ASX Opens on 1 December 2025

CSL closed at about A$186.30 on Friday, 28 November 2025, with shares down roughly 34% for the year and market cap near A$90 billion. The stock remains under pressure after an October profit downgrade, a delayed Seqirus spin-off, and a 42% shareholder protest vote against executive pay. Trading volume approached 700,000 shares. Management has launched a major buyback and a US$1.5 billion US expansion.

30 November 2025

ASX News·ASX:CSL·Stock Market

CSL Limited (ASX:CSL) Share Price Today, 28 November 2025 – Is the Worst Finally Priced In?

CSL Limited closed at A$187.6 on Friday, up 0.8% from Thursday, with over 138,000 shares traded. The stock remains down about 34% over the past year after profit downgrades, a delayed spin-off, and major cost-cutting. In late October, shares plunged 14–16% in one day after the company cut guidance and postponed the Seqirus spin-off. No new ASX announcements were issued Friday.

28 November 2025

ASX Updates·ASX:CSL

Previous 1 2 3 4 Next

Marvell Technology Shares Rise Nearly 5% on Positive Analyst Outlook and Nvidia Partnership
April 9, 2026, 7:32 PM EDT. Shares of Marvell Technology (NASDAQ: MRVL) rose nearly 5% on Thursday, driven by Barclays analyst Tom O'Malley's bullish forecast on the company's optical components segment. O'Malley projects up to 90% growth in Marvell's optical-networking sales by 2026-2027, vital for AI infrastructure requiring fast data transmission. Marvell's $3.25 billion acquisition of Celestial AI and a $2 billion investment from Nvidia have strengthened its position in custom chip design and AI computing, fueling investor optimism. Nvidia's strategic partnership integrates Marvell's networking solutions into its AI platforms. Despite the surge, Motley Fool's Stock Advisor excluded Marvell from its current top 10 picks, highlighting significant returns from earlier recommendations like Netflix and Nvidia.

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026

MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026

Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026

Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026

NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.

Plug Power Stock Climbs After 2026 Profit Push, Up to $200M Cost-Cut Plan

9 April 2026

Plug Power shares rose 2.5% to $2.715 Thursday after the company reaffirmed its target of positive EBITDAS by end-2026 and projected up to $200 million in savings from Project Quantum Leap. The update followed a major electrolyzer project win in Quebec and investor meetings in Toronto and Montreal. Plug reported 2025 revenue of $710 million and a fourth-quarter gross profit of $5.5 million.

Go toTop

ASX:CSL 28 November 2025 - 22 December 2025

Stock Market Today

Latest article